(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
22 May 2025 (22.05.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/106658 A1

(51) International Patent Classification:
C07K 16/30 (2006.01) *A61P 35/00* (2006.01)
A61K 47/68 (2017.01)

(21) International Application Number:
PCT/US2024/055905

(22) International Filing Date:
14 November 2024 (14.11.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/599,497 15 November 2023 (15.11.2023) US
63/608,755 11 December 2023 (11.12.2023) US

(71) Applicant: **EXELIXIS, INC.** [US/US]; 1851 Harbor Bay Parkway, Alameda, CA 94502 (US).

(72) Inventor: **PETERSON, Amy**; c/o Exelixis, Inc., 1851 Harbor Bay Parkway, Alameda, CA 94502 (US).

(74) Agent: **CAMPBELL, A., Patricia** et al.; Jones Day, 250 Vesey Street, New York, NY 10281-1047 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: 5T4 ANTIBODY DRUG CONJUGATES AND METHODS OF THEIR USE



FIG. 1

(57) Abstract: Provided are methods of treating cancer with a 5T4 ADC optionally in combination with a PD-L1/PD-1 inhibitor, such as pembrolizumab. Cancers treated include breast cancer, endometrial cancer, head and neck cancer, pancreatic cancer, lung cancer, prostate cancer, cervical cancer, bladder cancer, renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), and colorectal cancer.

[Continued on next page]

WO 2025/106658 A1

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*